Development of antibodies to interferon beta in patients: Technical and biological aspects

European Cytokine Network

Volumn 10, Issue 3, 1999, Pages 413-422

  Antonelli, Guido ^a,b   Dianzani, Ferdinando ^b,c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Antibodies to interferon alpha; Antibodies to interferon beta; Interferon alpha; Interferon beta; Interferon beta therapy; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; NEUTRALIZING ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CANCER; HUMAN; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; QUANTITATIVE ASSAY; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

AUTOANTIBODIES; HUMANS; IMMUNOASSAY; INTERFERON-BETA; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY;

EID: 0032871741     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Avrameas S. 1991. Natural autoantibodies: from "horror autotoxicus" to "gnothi seauton". (Review) Immunol. Today 12: 154.
2. Bendtzen K, Svenson M, Jonsson V, Hippe E. 1990. Autoantibodies to cytokines: friends or focs? (Review) Immunol. Today 11: 167.
3. Gribben J G, Devereux S, Thomas N S, Keim M, Jones H M, Goldstone AH, Linch D C. 1990. Development of antibodies to unprotected glycolysation sites on recombinant human GM-CSF. Lancet 335: 434.
4. Bendtzen K, Hansen M B, Diamant M, Ross C, Svenson M. 1994. Naturally occurring autoantibodies in interleukin-1 alpha, interleukin-6, interleukin-10 and interferon-alpha. J Interferon Res. 14: 157.
5. Kearney J F. 1994. Formation of autoantibodies, including anti-cytokine antibodies, is a hallmark of the immune response of early B cells. J. Interferon Res. 14: 151.
6. Lusher J M. 1994. Human antibodies to recombinant factor VIII in hemophiliacs. J. Interferon Res. 14: 173.
7. Fineberg S, Galloway I J, Fineberg N, et al. 1983. Immunogenicity of recombinant DNA human insulin. Diabetologia 25: 465.
8. Meager A. 1994. Human antibodies to insulin in diabetes. J. Interferon Res. 14: 181.
9. Peces R, de la Torre M, Alcazar R, Urra J M. 1996. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N. Engl. J. Med. 335: 523.
10. Revoltella R P. 1998. Natural and therapeutically-induced antibodies to cytokines. (Review) Biotherapy 10: 321.
11. The Lenercept MS Study Group, the University of British Columbia MS/MRI Analysis Group. Can. J. Neurol. Sci. 1998: 25 (Suppl 2): 531.
12. Francis G S for the Lenercept MS Study Group. 1998. Inhibition of TNF-alpha in relapsing MS increases clinical relapses. Mult. Scler. 4: 1099.
13. De Maeyer-Guignard J, De Maeyer E. 1986. Natural antibodies to interferon-alpha and interferon-beta are a common feature of inbred mouse strains. J. Immunol. 136: 1708.
14. Ross C, Hansen M B, Schyberg T, Berg K. 1990. Autoantibodies to crude human leukocyte interferon (IFN), recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin. Exp. Immunol. 82: 57.
15. Caruso A, Bonfanti C, Colombrioita D, de Fracesco H, de Rango C, Foresti I, et al. 1990. Natural antibodies to IFN-gamma in man and their increase during viral infection. J. Immunol. 144: 685.
16. Ross C, Svenson M, Hansen M B, Vejlsgaard G L, Bendtzen K. 1995. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 95: 1974.
17. Sedmak J J, Grossberg S E. 1989. High levels of circulating neutralizing antibody in normal animals to recombinant mouse interferon-beta produced in yeast. J. Interferon Res. 9 (Suppl 1): S61.
18. Panem S, Check I J, Henriksen D, Vilcek J. 1982. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129: 1.
19. Meager A, Vincent A, Newsom-Davis J, Willcox N. 1997. Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 350: 1596.
20. Ikeda Y, Toda G, Hashimoto N, Umeda N, Miyake K, Yamanaka M, Kurokowa K. 1991. Naturally occurring anti-interferon alpha 2a antibodies in patients with acute viral hepatitis. Clin. Exp. Immunol. 85: 80.
21. Trown P W, Kramer M J, Dennin R A Jr, et al. 1983. Antibodies to human leukocyte interferons in cancer patients. Lancet i: 81.
22. Prummer O, Bunjes D, Wiesneth M, Arnold R, Porzsolt F, Heimpel H. 1994. High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transportation. Bone Marrow Transplant 14: 483.
23. Gresser I, Tovey MG, Bandu TM, et al. 1976. Role of interferon in the pathogenesis of virus disease as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144: 135.
24. Antonelli G. 1997. In vivo development of antibody to interferons: an update to 1996. J. Interferon Cytokine Res. 17: S39.
25. Catani L, Gugliotta L, Zauli G, Bagnara GP, Antonelli G, Belmonte MM, et al. 1992. In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia. Haematol 77: 318.
26. Prummer O, Streichan U, Heimpel H, Porzsolt F. 1994. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies. J. Immunol. Meth. 171: 45.
27. Mire-Sluis A R, Page L A, Meager A, Igaki J, Lee J, Lyons S, Thorpe R. 1996. An anti-cytokine bioactivity assay for interferons-alpha, -beta and -omega. J. Immunol. Meth. 195: 55.
28. Pungor E Jr, Files JG, Gabe JD, Do L T, Foley W P, Gray J L, Nelson J W, Nestaas E, Taylor J L, Gossburg S E. 1998. A novel bioassay for the determination of neutralizing antibodies to IFN-beta 1b. J. Interferon Cytokine Res. 18: 1025.
29. Grossberg S E, Kawade Y. 1997. The expression of potency of neutralizing antibodies for interferons and other cytokines. (Review) Biotherapy 10: 93.
30. von Wussow P, Jakschies D, Freund M, Deicher H. 1989. Humoral response to recombinant interferon alpha 2b in patients receiving recombinant interferon alpha 2b therapy. J. Interferon Res. 9: S25.
31. Antonelli G, Simeoni E, Artini M, Turriziani O, Dianzani F. 1997. Pharmacokinetics of recombinant interferon (IFN)-α in a hepatitis patient with neutralizing antibody to IFN. Hepatol. Res. 8: 149.
32. Kivisakk P, Alm G V, Tian W Z, Matusevicius D, Fredrikson S, Link H. 1997. Neutralising and binding anti-interferon-beta-1 b (IFN-beta-1 b) antibodies during IFN-beta-1 b treatment of multiple sclerosis. Mult Scler 3: 184.
33. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, De Pisa F, Fieschi C, Gasparini C, Salvetti M, Dianzani F. 1998. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta 1a. J. Interferon Cytokine Res. 18: 345.
34. Cebrian M, Yague E, de Landaduri M O, Rodriguez-Moya M, Fresno M, Pezzin N, et al. 1987. Different functional sites on rIFN-alpha 2 and their relation to the cellular receptor binding site. J. Immunol. 138: 484.
35. Redlich P N, Hoeprich P D Jr, Colby D B, Grossberg S E. 1991. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc. Natl. Acad. Sci. USA 88: 4040.
36. Ziai M R, Imberti L, Kobayashi M, Perussia B, Trinchieri G, Feronne S. 1986. Distinct functional domain on the recombinant human immune interferon molecule. Cancer Res. 46: 6187.
37. Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, Schiraldi O, Dianzani F. 1994. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin. Exp. Immunol. 97: 4.
38. Viscomi G C, Grimaldi M, Palazzini E, Silvestri S. 1995. Human leukocyte IFN-alpha: structure, pharmacology and therapeutic applications. (Review) Med. Res. Rev. 15: 445.
39. Ronnblom L E, Janson E T, Peters A, Oberg K E, Alm G V. 1992. Characterisation of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin. Exp. Immunol. 89: 330.
40. Brand C M, Leadbeater L, Bellati G, Marotta F, Ideo G. 1993. Antibodies developing against a single recombinant interferon protein may neutralize other interferon-alpha subtypes. J. Interferon Res. 13: 121.
41. Antonelli G, Gianelli G, Currenti M, et al. 1995. Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN-alpha 2 and retreated with lymphoblastoid IFN-alpha. Intern. Hepatol. Commun. 4: 232.
42. Nolte K U, Frank R, Guenther G, et al. 1994. Human therapy-induced anti-IFN antibodies neutralize rIFN-alpha2 by binding to its N-terminal functional domain. J. Interferon Res. 14 (Suppl 1): S118.
43. Medenica R D, Mukerjee S, Huschart T, Corbitt W. 1994. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis. J. Clin. Apheresis 9: 216.
44. Havredaki M, Barona F. 1985. Variations of interferon activators and/or inhibitors in human scram and their relationship to interferon therapy. Jpn. J. Med. Sci. Biol. 38: 107.
45. Lok A S, Lai C L, Leung E K. 1990. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12: 1266.
46. Jacobs S, Friedman R M, Nagabhushan T L, et al. 1989. Detection of serum neutralizing antibodies to interferon alfa-2b (Intron A) by means of an enzyme immunoassay. J. Interferon Res. (Suppl 2) 9: S292.
47. Larocca A P, Leung S C, Marcus SG, Colby C B, Borden E C. 1989. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta. J. Interferon Res. 9: S51.
48. Itri L M, Sherman H I, Pallcroni A U, Evans L M, Tran L L, Campion M, Chizzonite R. 1987. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha 2a. J. Interferon Res. 9 (Suppl) 59.
49. Steis R G, Smith J W 2d, Urba W J, Clark JW, Itri L M, Evans L M, Schoenberger C, Longo D L, et al. 1988. Resistance to recombinant interferon-alpha-2a in hairy cell leukemia associated with neutralizing anti-interferon-antibodies. N. Engl. J. Med. 318: 1409.
50. Figlin R A, Itri L M. 1988. Anti-interferon-antibodies: a perspective. (Review) Semin. Hematol. 25: 9.
51. Antonelli G, Currenti M, Turriziani O, Dianzani F. 1991. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163: 882.
52. Oberg K, Alm G V. 1989. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant curcinoid tumors. J. Interferon Res. 9: S45.
53. Quesada J R, Rios A, Swanson D, Trown P, Gutterman J U. 1985. Antitumor activity of recombinant derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3: 1522.
54. von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. 1987. Clinical significance of anti-interferon antibodies during interferon therapy. Lancet 2: 635.
55. Casato M, Lagan B, Antonelli G, Dianzani F, Bonomo L. 1991. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 78: 3142.
56. von Wussow P, Pralle H, Hochkeppel D, Jakschies D, Sonnen S, Schmidt H, et al. 1991. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. Blood 78: 38.
57. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, et al. 1993. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13: 146.
58. Brand C M, Leadbeater L, Budiman R, Lechner K, Gisslinger H. 1994. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid alpha 1 and in vitro studies on the specificity of the antibodies. Br. J. Haematol. 86: 216.
59. Antonelli G, Gianelli G, Pistello M, Maggi F, Vatteroni L, Currenti M, et al. 1994. Clinical significance of recombinant interferon alpha 2 neutralizing antibodies in hepatitis patients. J. Interferon Res. 14: 211.
60. McSweeney E N, Giles F J, Goldstone A H. 1994. Recombinant interferon alpha 2 antibodies in chronic lymphocytis leukemia. J. Interferon Res. 14: 191.
61. Prummer O, Porzsolt F. 1994. Recombinant interferon alpha 2 antibodies in renal cell carcinoma. Delta-p study group. J. Interferon Res. 14: 193.
62. Bonetti P, Diodati G, Drago C, Casarin C, Scaccabarozzi S, Realdi G, Alberti A, et al. 1994. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. J. Hepatol. 20: 416.
63. Antonelli G, Gianelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, et al. 1996. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha 2 therapy. Clin. Exp. Immunol. 104: 384.
64. Roffi L, Mels G C, Antonelli G, Bellati G, Panizzuti F, Piperno A, et al. 1995. Breakthrough during recombinant alpha-interferon therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. Hepatol. 21: 645.
65. Craxi A, Di Marco V, Volpes R, Palazzo U. 1988. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepatogastroenterology 35: 304.
66. Brook M G, McDonald J A, Karayannis P, Caruso L, Forster G, Harris J R, Thomas H C. 1989. Randomised controlled trial of interferon alpha 2a (rbc) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 30: 1116.
67. von Wussow P, Hartman F, Freund P, Poliwoda H, Deicher H. 1988. Leukocyte derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b. Lancet 1: 882.
68. Rosenblum M G, Unger B W, Gutterman J U, Hersh E M, David G S, Frineke J M. 1985. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res. 45: 2421.
69. Borden E C, Wadler S. 1996. Interferons as biochemical modulators. J. Clin. Oncol. 14: 2627.
70. Borden E C, Parkinson D. 1996. Interferons: effectiveness, toxicities, and costs. Ann. Intern. Med. 125: 614.
71. Colby C B, Inoue M, Thompson M, Tan Y H. 1984. Immunologic differentiation between E. coli and CHO cell-derived recombinant and natural human beta-interferons. J. Immunol. 133: 3091.
72. Teitelbaum A P, Langton B C, Hung J, et al. 1987. Antibody measurements in patients treated with recombinant interferon-beta. Proc. AACR 28: 406.
73. Konrad M W, Childs A L, Merigan T C, Borden E C. 1987. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J. Clin. Immunol. 7: 365.
74. Dummer R, Muller W, Nestle F, Wiede J, Dues J, Lechner W, et al. 1991. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67: 2300.
75. Knobler R L, Greenstein J I, Johnson K P, Lublin F D, Panitch H S, Conway K, et al. 1993. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Res. 13: 333.
76. Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G. 1994. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol. Immunother. 39: 263.
77. Jacobs L D, Cookfair D L, Rudick R A, et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol. 39: 285.
78. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47: 889.
79. Bornstein J, Pascal B, Zarfati D, Goldschmid N, Abramovici H. 1997. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled studÿ of intralesional therapy. Int J STD AIDS 8: 614.
80. Abdul-Ahad A K, Galazka A R, Revel M, Biffoni M, Borden E C. 1997. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell. Mol. Ther. 3: 27.
81. PRISMS Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498.
82. Ross C, Svenson M, Kock-Henricksen N, Soelberg-Serensen P, Skovgard G L, Bendtzen K. 1998. A randomized comparative study of antibody development to IFN-beta 1a and IFN-beta 1b in patients with multiple sclerosis. Eur. Cytokine Netw. 9 (3): 502.
83. Hochuli E. 1997. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J. Interferon Cytokine Res. 17 (Suppl 1): S15.
84. Braun A, Kwee L, Labow M A, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon-alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14: 1472.
85. Goelz S E, Runkel L, Meier W et al. 1998. Structural analysis of human interferon-beta (IFN-beta): implications for the immunogenicity between IFN-beta-1a and IFN-beta 1b. Neurology 50: A342.
86. Runkel L, Meier W, Pepinski RB, Karpusas M, Whitty A, Kihball K, et al. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15: 641.
87. Khan O A, Dhib-Jalbut S S. 1998. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 51: 1698.
88. Antonelli G, Simeoni E, Bagnato F, et al. 1998. Anti-interferon (IFN) antibodies in patients with relapsing remitting multiple sclerosis treated with recombinant IFN-beta 1a or IFN-beta 1b. Eur. Cytokine Netw. 9 (3): 337.
89. Runkel L, Meier W, Pepinsky R B, Karpusas M, Whitty A, Kimball K, et al. 1998. Structural and functional differences between glycosylated and nonglycosilated forms of human interferon-beta (IFN-beta). Pharm. Res. 15: 641.